Stock Events

Histogen 

$0.21
28
+$0.01+4.48% Friday 18:17

Statistics

Day High
0.21
Day Low
0.21
52W High
1.05
52W Low
0.05
Volume
287
Avg. Volume
16,688
Mkt Cap
897,069
P/E Ratio
-0.07
Dividend Yield
-
Dividend
-

Earnings

9NovConfirmed
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
-1.7
-1.2
-0.7
-0.2
Expected EPS
-0.54
Actual EPS
-0.9

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HSTO. It's not an investment recommendation.
Alphabet
63772
GOOGL
Apple
56875
AAPL
Microsoft
52480
MSFT
Amazon
48580
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ocugen
OCGN
Mkt Cap491.5M
Ocugen is involved in developing gene therapies for retinal diseases, competing with Histogen's regenerative medicine approach.
Pfizer
PFE
Mkt Cap162.29B
Pfizer, with its broad range of healthcare products, including treatments in dermatology and regenerative medicine, competes in some areas with Histogen.
Regeneron Pharmaceuticals
REGN
Mkt Cap106.03B
Regeneron Pharmaceuticals focuses on regenerative medicine and biologics, directly competing with Histogen's product offerings.
Abbvie
ABBV
Mkt Cap293.88B
AbbVie, through its aesthetics portfolio, competes with Histogen's hair growth and dermatological products.
AMGEN
AMGN
Mkt Cap167.62B
Amgen, with its focus on human therapeutics, has products that compete in the regenerative medicine space with Histogen.
Biomarin Pharmaceutical
BMRN
Mkt Cap14.73B
BioMarin Pharmaceutical targets rare diseases with gene therapies, overlapping with Histogen's regenerative medicine focus.
Gilead Sciences
GILD
Mkt Cap84.37B
Gilead Sciences, with its work in cell therapy and regenerative medicine, competes with Histogen's approach to treatment.
Vertex Pharmaceuticals
VRTX
Mkt Cap114.89B
Vertex Pharmaceuticals, focusing on cell and genetic therapies, has a competitive edge in the same field as Histogen.
Novartis
NVS
Mkt Cap224.62B
Novartis, with its advanced therapy medicinal products, competes in the regenerative medicine and dermatology space against Histogen.

About

Health Technology
Biotechnology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Show more...
CEO
Steven Mento
Employees
7
Country
US
ISIN
US43358Y2028
WKN
000A3DMJS

Listings

OTCM
US
HSTO